Aurobindo Pharma ties up with BIRAC to develop coronavirus vaccine

Aurobindo Pharma on Tuesday announced collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology for the development of Covid vaccine

Coronavirus, vaccine, covid
Press Trust of India New Delhi
2 min read Last Updated : Sep 15 2020 | 5:42 PM IST

Aurobindo Pharma on Tuesday announced collaboration with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology for the development of COVID-19 vaccine.

BIRAC has facilitated the establishment of 'the r-VSV vaccine' manufacturing platform for the first time in India by supporting Aurobindo Pharma's COVID-19 vaccine development, the company said in a regulatory filing.

Aurobindo Pharma said it is developing a vaccine for COVID-19 through its wholly-owned US subsidiary, Auro Vaccines. The vaccine candidate is based on a proprietary vaccine delivery platform of the company.

"Aurobindo is in the process of setting up a state-of-art manufacturing facility for viral vaccineswhich will be used to produce the COVID-19 vaccine and other viral vaccines. The plant will comply with global standards. The company's COVID-19 vaccine development is going as per plan," the filing added.

Commenting on the collaboration, Aurobindo Pharma Managing Director N Govindarajan said," It is a matter of immense pride that BIRAC has placed its trust on our vaccine capabilities. The senior leadership of Aurobindo and Auro Vaccines has extensive experience in development, production and commercialization of several vaccines."

Department of Biotechnology Secretary and BIRAC Chairperson Renu Swarup said the partnership with Aurobindo is to serve the country's need for a vaccine to fight this pandemic.

"The government is focussed on creating an ecosystem that nurtures and encourages new product innovation to address the most relevant issues to our society," Swarup added.

Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the pharma firms in India working on the coronavirus vaccine.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineAurobindo PharmaBirac

First Published: Sep 15 2020 | 5:41 PM IST

Next Story